Susan Kirkland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susan Kirkland has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Tewis Bouwmeester
Novartis Institutes for BioMedical Research, Basel 4056, Switzerland
2 shared publicationsAdrian Salathe
Novartis Institutes for BioMedical Research, Basel 4056, Switzerland
1 shared publication- Adrian Salathe
Novartis Institutes for BioMedical Research, Basel, Switzerland
1 shared publication Aimee Reynolds
Novartis Institutes for BioMedical Research, Cambridge, Cambridge, MA, USA
1 shared publication- Alexandra Aebi
Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
1 shared publication - Alfred Zimmerlin
Novartis Institutes for BioMedical Research, Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity
- 18 January 2021
- Published by Springer Nature in Nature Chemical Biology
- Vol. 17 (3) , 280-290
BET bromodomain inhibitors regulate keratinocyte plasticity
Although most acute skin wounds heal rapidly, non-healing skin ulcers represent an increasing and substantial unmet medical need that urgently requires effective therapeutics. Keratinocytes resurface wounds to re-establish the epidermal barrier by transitioning to an activated, migratory state, but this ability is lost in dysfunctional chronic wounds. Small-molecule regulators of keratinocyte plasticity with the potential to reverse keratinocyte malfunction in situ could offer a novel therapeutic approach in skin wound healing. Utilizing high-throughput phenotypic screening of primary keratinocytes, we identify such small molecules, including bromodomain and extra-terminal domain (BET) protein family inhibitors (BETi). BETi induce a sustained activated, migratory state in keratinocytes in vitro, increase activation markers in human epidermis ex vivo and enhance skin wound healing in vivo. Our findings suggest potential clinical utility of BETi in promoting keratinocyte re-epithelialization of skin wounds. Importantly, this novel property of BETi is exclusively observed after transient low-dose exposure, revealing new potential for this compound class.
- 18 January 2021
- Published by Springer Nature in Nature Chemical Biology
- Vol. 17 (3) , 280-290
BET bromodomain inhibitors regulate keratinocyte plasticity
Although most acute skin wounds heal rapidly, non-healing skin ulcers represent an increasing and substantial unmet medical need that urgently requires effective therapeutics. Keratinocytes resurface wounds to re-establish the epidermal barrier by transitioning to an activated, migratory state, but this ability is lost in dysfunctional chronic wounds. Small-molecule regulators of keratinocyte plasticity with the potential to reverse keratinocyte malfunction in situ could offer a novel therapeutic approach in skin wound healing. Utilizing high-throughput phenotypic screening of primary keratinocytes, we identify such small molecules, including bromodomain and extra-terminal domain (BET) protein family inhibitors (BETi). BETi induce a sustained activated, migratory state in keratinocytes in vitro, increase activation markers in human epidermis ex vivo and enhance skin wound healing in vivo. Our findings suggest potential clinical utility of BETi in promoting keratinocyte re-epithelialization of skin wounds. Importantly, this novel property of BETi is exclusively observed after transient low-dose exposure, revealing new potential for this compound class.